Last reviewed · How we verify
Targeted Systemic Therapy
Targeted Systemic Therapy is a cancer treatment designed to selectively target and destroy malignant cells while minimizing damage to healthy tissue.
Targeted Systemic Therapy is a cancer treatment designed to selectively target and destroy malignant cells while minimizing damage to healthy tissue. Used for Cancer (specific indication unknown).
At a glance
| Generic name | Targeted Systemic Therapy |
|---|---|
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This is a broad category descriptor rather than a specific drug, referring to systemic cancer therapies that employ targeting strategies such as antibody-drug conjugates, receptor-targeted small molecules, or immunotherapies. The exact mechanism depends on the specific therapeutic agent being developed, but generally involves binding to tumor-associated antigens or pathways and delivering cytotoxic effects preferentially to cancer cells.
Approved indications
- Cancer (specific indication unknown)
Common side effects
Key clinical trials
- Inflammatory Markers in Lumbar Radicular Pain Treated With PRF and TFESI
- Prospective Evaluation of Targeted Axillary Dissection (TAD) (NA)
- Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy (PHASE2)
- BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis (PHASE2)
- PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer (PHASE2, PHASE3)
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy (PHASE3)
- Safety of PiggyBac Transposon CAR T-cells Targeting CD-19 in Refractory Lupus. (PHASE1)
- Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: